Literature DB >> 22115524

[ESC/EAS Guidelines for the management of dyslipidaemias].

Željko Reiner1, Alberico L Catapano, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegría, M John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs Hobbs, John Kjekshus Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F Storey, Wood David.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22115524     DOI： 10.1016/j.recesp.2011.09.014

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN： 0300-8932            Impact factor:   4.753


× No keyword cloud information.
  11 in total

1.  Post-mortem investigation of young deceased individuals with ischemic heart disease-outcome of supplementary genetic testing for dyslipidemia.

Authors:  C L Hertz; S L Christiansen; G L Ottesen; R Frank-Hansen; H Bundgaard; N Morling
Journal:  Int J Legal Med       Date:  2015-10-21       Impact factor: 2.686

2.  Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction.

Authors:  Ingrid Brænne; Mariana Kleinecke; Benedikt Reiz; Elisabeth Graf; Tim Strom; Thomas Wieland; Marcus Fischer; Thorsten Kessler; Christian Hengstenberg; Thomas Meitinger; Jeanette Erdmann; Heribert Schunkert
Journal:  Eur J Hum Genet       Date:  2015-06-03       Impact factor: 4.246

3.  Development of job standards for clinical nutrition therapy for dyslipidemia patients.

Authors:  Min-Jae Kang; Jung-Sook Seo; Eun-Mi Kim; Mi-Sun Park; Mi-Hye Woo; Dal-Lae Ju; Gyung-Ah Wie; Song-Mi Lee; Jin-A Cha; Cheong-Min Sohn
Journal:  Clin Nutr Res       Date:  2015-04-27

4.  Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study.

Authors:  Takashi Miura; Atsushi Izawa; Hirohiko Motoki; Yusuke Miyashita; Yuichiro Kashima; Souichiro Ebisawa; Takeshi Tomita; Jun Koyama; Uichi Ikeda
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

5.  Whole-exome sequencing in an extended family with myocardial infarction unmasks familial hypercholesterolemia.

Authors:  Ingrid Brænne; Benedikt Reiz; Anja Medack; Mariana Kleinecke; Marcus Fischer; Salih Tuna; Christian Hengstenberg; Panos Deloukas; Jeanette Erdmann; Heribert Schunkert
Journal:  BMC Cardiovasc Disord       Date:  2014-08-26       Impact factor: 2.298

6.  Polydextrose changes the gut microbiome and attenuates fasting triglyceride and cholesterol levels in Western diet fed mice.

Authors:  Ghulam Shere Raza; Heli Putaala; Ashley A Hibberd; Esa Alhoniemi; Kirsti Tiihonen; Kari Antero Mäkelä; Karl-Heinz Herzig
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379

7.  Effects of prolonged exercise versus multiple short exercise sessions on risk for metabolic syndrome and the atherogenic index in middle-aged obese women: a randomised controlled trial.

Authors:  JinWook Chung; KwangJun Kim; Jeeyoung Hong; Hyoun-Joong Kong
Journal:  BMC Womens Health       Date:  2017-08-22       Impact factor: 2.809

8.  Fenofibrate modified-release pellets with lag phase and high oral bioavailability.

Authors:  Fang Li; Xin Zheng; YongChu Bao; Ting Chen; Jia Zeng; XiaoLi Xu; Chao Yan; LingLin Feng
Journal:  Drug Des Devel Ther       Date:  2018-12-24       Impact factor: 4.162

9.  Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.

Authors:  Yanli Wang; Liang Bai; Yan Lin; Yulong Chen; Hua Guan; Ninghong Zhu; Yafeng Li; Shoucui Gao; Lijing Sun; Sihai Zhao; Jianglin Fan; Enqi Liu
Journal:  Lipids Health Dis       Date:  2015-07-29       Impact factor: 3.876

10.  Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J.

Authors:  Masato Nakamura; Junya Ako; Hidenori Arai; Atsushi Hirayama; Atsushi Nohara; Yoshitaka Murakami; Asuka Ozaki; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-02-21       Impact factor: 4.928
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.